Trial · NCT01801358
Results by group186
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 186
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 150 mg Bid + MEK162 45 mg Bid (DDS) | Anaemia | 0 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 200 mg Bid + MEK162 45 mg Bid (DDS) | Anaemia | 0 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 300 mg Bid + MEK162 30 mg Bid (DDS) | Anaemia | 0 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 300 mg Bid + MEK162 45 mg Bid (DDS) | Anaemia | 1 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 350 mg Bid + MEK162 30 mg Bid (DDS) | Anaemia | 0 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 400 mg Bid + MEK162 30 mg Bid (DDS) | Anaemia | 0 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 150 mg Bid + MEK162 45 mg Bid (DDS) | Diarrhoea | 0 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 200 mg Bid + MEK162 45 mg Bid (DDS) | Diarrhoea | 0 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 300 mg Bid + MEK162 30 mg Bid (DDS) | Diarrhoea | 2 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 300 mg Bid + MEK162 45 mg Bid (DDS) | Diarrhoea | 1 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 350 mg Bid + MEK162 30 mg Bid (DDS) | Diarrhoea | 0 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 400 mg Bid + MEK162 30 mg Bid (DDS) | Diarrhoea | 0 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 150 mg Bid + MEK162 45 mg Bid (DDS) | Vomiting | 0 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 200 mg Bid + MEK162 45 mg Bid (DDS) | Vomiting | 0 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 300 mg Bid + MEK162 30 mg Bid (DDS) | Vomiting | 0 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 300 mg Bid + MEK162 45 mg Bid (DDS) | Vomiting | 1 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 350 mg Bid + MEK162 30 mg Bid (DDS) | Vomiting | 1 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 400 mg Bid + MEK162 30 mg Bid (DDS) | Vomiting | 1 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 150 mg Bid + MEK162 45 mg Bid (DDS) | Nausea | 0 | DLTs | |
| Phase Ib: Incidence of Dose Limiting Toxicities (DLT) During the First Cycle | Phase Ib: AEB071 200 mg Bid + MEK162 45 mg Bid (DDS) | Nausea | 0 | DLTs |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01801358/results